Table 1.
Avian leukosis virus (ALV) vaccine trials.
| ALV strain | Vaccine components | Adjuvant | Results summary | Immunological target | Reference |
|---|---|---|---|---|---|
| J | Recombinant ALV-J gp85 protein | Liposomes | High antibody levels; 58.3% (inoculation once) and 83.3% (inoculation twice) protection ratios | Neutralizing antibody | (59) |
| J | Recombinant ALV-J gp85 protein | Cytosine-phosphate-guanine oligodeoxynucleotide (CpG-ODN) | Inducing breeder hens to produce effective maternal antibody that protected the hatched chickens against early ALV-J infection (70% protection ratios) | Neutralizing antibody | (60) |
| J | Recombinant chimeric multi-epitope protein X | Freund’s adjuvant | 80% protection ratios | Neutralizing antibody and cellular responses | (61) |
| J | DNA vaccine with chimeric multi-epitope DNA | Freund’s adjuvant | 70% protection ratios | Neutralizing antibody and cellular responses | (62) |
| A | Recombinant ALV-A gp85 protein | CpG-ODN | Inducing the breeder hens to produce better neutralizing antibody responses and protect 80% of their offspring chickens against early infection | Neutralizing antibody | (69) |
| B | Inactivated ALV-B vaccine | Oil | Inducing antibody reaction to ALV-B and providing maternal antibodies to 1-day-old chickens against early infection of ALV-B | Neutralizing antibody | (68) |